A review of the cardiac systemic side-effects of antihistamines: ebastine.

@article{Moss1999ARO,
  title={A review of the cardiac systemic side-effects of antihistamines: ebastine.},
  author={A J Moss and Paul Chaikin and Joel Dorantes Garc{\'i}a and Michael Gillen and Derek J Roberts and Joel Morganroth},
  journal={Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology},
  year={1999},
  volume={29 Suppl 3},
  pages={200-5}
}
The cardiac safety of ebastine, a long-acting, non-sedating antihistamine, has been thoroughly assessed in phase I-III clinical studies. Ebastine alone at the recommended doses of 10 mg and 20 mg has no clinically relevant effect on QTc interval in adults and in special patient populations (elderly, children or subjects with hepatic or renal impairment). Ebastine administered at 60 and 100 mg/day (3-5 times the maximum recommended dose) for 1 week had statistically significantly smaller effects… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Similar Papers

Loading similar papers…